Case Study: Mapping the Clinical Path in Rheumatoid Arthritis with Real World Data
The growing accessibility of healthcare Real World Data (RWD) has opened up previously unimaginable resources for uncovering pharmaceutical market dynamics. Despite the increasing availability of RWD, its utilization remains extremely challenging. The data is expensive to buy, laborious to process, and requires a great deal of analytical and therapeutic expertise to turn into meaningful, actionable insights. But done right, RWD has the potential to boost brand performance, fine-tune commercial strategy, tease out subtle market nuances, and unlock hidden opportunities.
In this case study we explore how US claims and EHR data can be used to create a detailed roadmap of the treatment journey and provide understanding of the therapeutic landscape for Rheumatoid Arthritis.
Download this case study to better understand:
- Treatment initiation and progress
- Humira patient share by line of therapy
- Trends in second-line patient share
- Newly diagnosed patient treatment flow
- Patient demographics
- Laboratory testing, risk factors, and co-morbidities
- Co-prescribed therapies
- Payer and cost analysis
Please complete the form below to access your download.
RELATED DRG CONTENT